Mona is a General Partner of OrbiMed and has been with OrbiMed since 2010. Prior to OrbiMed, Mona covered the biotechnology industry as a member of J.P. Morgan’s biotechnology equity research team. Her previous experience includes positions at the Global Alliance for TB Drug Development and the Harvard Business School. She has also published scientific articles in various peer-reviewed journals. Mona earned a B.A. degree from the University of California at Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and was a post-doctoral fellow at the Dana Farber Cancer Institute where her research focused on mechanisms of programmed cell death.
